Combined catechol-O-methyltransferase and μ-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects

Anesthesia and Analgesia

Volumn 112, Issue 2, 2011, Pages 448-453

  Kolesnikov, Yuri ^a   Gabovits, Boris ^a   Levin, Ariel ^a   Voiko, Edward ^a   Veske, Andres ^b  

^a East Tallinn Central Hospital   (Estonia)

^b TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; CATECHOL METHYLTRANSFERASE; DNA; FENTANYL; METOCLOPRAMIDE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; ONDANSETRON; PETHIDINE; PROPOFOL;

ABDOMINAL SURGERY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; FEMALE; GENE MUTATION; GENERAL ANESTHESIA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NAUSEA; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE ANALGESIA; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RATING SCALE; RECOVERY ROOM; SEDATION; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL PATIENT; TREATMENT RESPONSE;

EID: 79251624059     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e318202cc8d     Document Type: Article

References (31)

1. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1. Clinical considerations. J Pain Symptom Manage 2001;21:144-50
2. Mercadante S, Portenoy PK. Opioid poorly-responsive cancer pain. Part 2. Basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage 2001;21:255-64
3. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage 2005;29:2-9
4. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998;95:9608-13
5. Beyer A, Koch T, Schröder H, Schulz S, Höllt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004;89:553-60
6. Janicki PK, Schuler G, Francis D, Bohr A, Gordin V, Jarzembowski T, Ruiz-Velasco V, Mets B. A genetic association study of the functional A118G polymorphism of the human opioid receptor gene in patients with acute and chronic pain. Anesth Analg 2006;103:1011-7
7. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006;105:334-7
8. Sia A, Lim Y, Lim EC, Goh RW, Law HY, Landau R, Teo YY, Tan EC. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patientcontrolled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008;109:520-6
9. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-50
10. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D. COMTval158met genotype affects mu opioid neurotransmitter responses to a pain stressor. Science 2003;299:1240-3
11. Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F. The val158met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005;116:73-8
12. Reyes-Gibby CC, Shete S, Rakvag T, Bhat S, Skorpen F, Bruera E, Kaasa S, Klepstad P. Exploring joint effects of gene and the clinical efficacy of morphine for cancer pain. Pain 2007;130:25-30
13. Chang VT, Hwang SS, Feuerman M. Validation Edmonton Symptom Assessment Scale. Cancer 2000;88:2164-71
14. Snustad DP, Simmons MJ. Principles of Genetics. 4th ed. New York: John Wiley & Sons, 2006
15. Xin L, Wang ZJ. Bioinformatic analysis of the human μ opioid receptor (OPRM1) splice and polymorphic variants. AAPS PharmSci 2002;4:1-13
16. Palmer SN, Giesecke NM, Body SC. Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology 2005;102:663-71
17. Stamer UM, Stuber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother 2007;8:2235-45
18. Gelernter J, Kranzler H, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol-and drug-dependent subjects. Mol Psychiatry 1999;4:476-83
19. Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, Du Bois R, Riley J. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005;5:324-36
20. Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain 1996;64:357-64
21. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry 1999;156:842-8
22. Bodnar RJ, Nicotera N. Neuroleptic and analgesic interactions upon pain and activity measures. Pharmacol Biochem Behav 1982;16:411-6
23. Calcutt CR, Doggett NS, Spencer PSJ. Modification of the antinociceptive activity of morphine by centrally administered ouabain and dopamine. Psychopharmacologia 1971;21:111-7
24. 2 receptor knockout mice: evidence for a tonically active anti-opioid system. J Neurosci 2001;21:7788-92
25. 3 adrenergic receptors. Pain 2007;128:199-208
26. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucoronide but not that of morphine. Pharmacogenetics 2002;12:3-9
27. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics. Clin Pharmacokinet 2004;43:983-1013
28. Pasternak G. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 2001;22:67-70
29. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1: recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33
30. Ross J, Riley J, Taegetmeyer AB, Sato H, Gretton S, du Bois RM, Welsh KI. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 2007;112:1390-403
31. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007;87:429-44